"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.
| Descriptor ID |
D007521
|
| MeSH Number(s) |
D08.811.682.047.820.475
|
| Concept/Terms |
Isocitrate Dehydrogenase- Isocitrate Dehydrogenase
- Dehydrogenase, Isocitrate
- NAD Isocitrate Dehydrogenase
- Dehydrogenase, NAD Isocitrate
- Isocitrate Dehydrogenase, NAD
- Isocitrate Dehydrogenase (NAD+)
|
Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".
This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 1 | 4 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 4 | 2 | 6 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.
-
Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated. Acta Neuropathol Commun. 2025 Jan 16; 13(1):9.
-
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025 Jan 12; 27(1):89-105.
-
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro Oncol. 2024 Dec 05; 26(12):2239-2255.
-
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplant. 2025 Feb; 60(2):154-160.
-
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplant. 2025 Feb; 60(2):144-153.
-
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis? Cancer Discov. 2024 Oct 04; 14(10):1768-1770.
-
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol. 2024 Oct 03; 26(10):1805-1822.
-
Sex-Specific Differences in Patients with IDH1-Wild-Type Grade 4 Glioma in the ReSPOND Consortium. AJNR Am J Neuroradiol. 2024 Sep 09; 45(9):1299-1307.
-
Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma. Cancer Cell. 2024 Oct 14; 42(10):1713-1728.e6.
-
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv. 2024 08 13; 8(15):4209-4220.